62937-47-7

Basic information

• Product Name: Z-D-PRO-NH2
• Synonyms: (R)-2-CARBAMOYL-1-CBZ-PYRROLIDINE;1-CBZ-D-PROLINAMIDE;Benzyloxycarbonyl-L-prolinamide, Carbobenzyloxy-L-prolinamide;(R)-2-Carbamoyl-1-N-Cbz-pyrrolidine;Cbz-D-prolinaMide;(R)-benzyl 2-carbamoylpyrrolidine-1-carboxylate;Cbz-D-Pro-NH2;(R)-Z-pyrrolidine-2-carboxylic acid amide
• CAS NO: 62937-47-7
• Molecular Formula: C₁₃H₁₆N₂O₃
• Molecular Weight: 248.28
• Product Categories: chiral;Chiral Reagent
• Mol File: 62937-47-7.mol

Chemical Properties

• Melting Point: 90-95 °C
• Boiling Point: 465.6 °C at 760 mmHg
• Flash Point: 235.4 °C
• Appearance: /
• Density: 1.263 g/cm³
• Vapor Pressure: 7.61E-09mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Store at RT.
• PKA: 15.95±0.20(Predicted)
• CAS DataBase Reference: Z-D-PRO-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: Z-D-PRO-NH2(62937-47-7)
• EPA Substance Registry System: Z-D-PRO-NH2(62937-47-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 62937-47-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H16N2O3/c14-12(16)11-7-4-8-15(11)13(17)18-9-10-5-2-1-3-6-10/h1-3,5-6,11H,4,7-9H2,(H2,14,16)/t11-/m1/s1

Upstream product

• 6404-31-5 Z-D-proline 
• 501-53-1 benzyl chloroformate 
• 344-25-2 D-Prolin 
• 15246-82-9 N-carbobenzoxy-(R)-proline-p-nitrophenol ester 
• 61350-62-7 N-benzyloxycarbonyl-D-proline acid chloride 
• 2812-47-7 pyrrolidine-2-carboxylic acid amide 

Downstream Products

• 57734-57-3 (-)-(R)-2-aminomethylpyrrolidine 
• 1140496-36-1 (R,E)-benzyl 2-(((dimethylamino)methylene)carbamoyl)pyrrolidine-1-carboxylate 
• 1140496-43-0 (R)-benzyl 2-(2-(4-chlorobenzyl)-5-methyl-2H-1,2,4-triazol-3-yl)pyrrolidine-1-carboxylate 
• 1137881-74-3 (R)-benzyl 2-(4-methylthiazol-2-yl)pyrrolidine-1-carboxylate 
• 1137881-73-2 (R)-benzyl 2-carbamothioylpyrrolidine-1-carboxylate 
• 1342299-30-2 N-((1R,2S)-1-hydroxy-3-phenyl-1-((R)-pyrrolidin-2-yl)propan-2-yl)-5-((R)-2-(4-methylthiazol-2-yl)pyrrolidine-1-carbonyl)chroman-7-carboxamide 
• 1342299-98-2 C₃₇H₄₆N₄O₆S 
• 1342299-93-7 (R)-tert-butyl 2-((1S,2S)-1-hydroxy-2-(6-((R)-2-(4-methylthiazol-2-yl)pyrrolidine-1-carbonyl)-2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxamido)-3-phenylpropyl)pyrrolidine-1-carboxylate 
• 702700-79-6 (R)-5-(pyrrolidin-2-yl)-1H-tetrazole 
• 839711-73-8 (2R)-2-(1H-tetrazol-5-yl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 62937-45-5 (R)-prolinamide 
• 620601-77-6 (+)-(R)-2-cyano-pyrrolidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

Catalyst Repurposing Sequential Catalysis by Harnessing Regenerated Prolinamide Organocatalysts as Transfer Hydrogenation Ligands

A catalyst repurposing strategy based on a sequential aldol addition and transfer hydrogenation giving access to enantiomerically enriched α-hydroxy-γ-butyrolactones is described. The combination of a stereoselective, organocatalytic step, followed by an efficient catalytic aldehyde reduction induces an ensuing lactonization to provide enantioenriched butyrolactones from readily available starting materials. By capitalizing from the capacity of prolineamides to act as both an organocatalyst and a transfer hydrogenation ligand, catalyst repurposing allowed the development of an operationally simple, economic, and efficient sequential catalysis approach.

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Total Synthesis of the Marine Natural Product Hemiasterlin by Organocatalyzed α-Hydrazination

An efficient synthesis of the potently cytotoxic marine peptide hemiasterlin is presented. The tetramethyltryptophan moiety is assembled by tert-prenylation of indole, followed by the high-yielding organocatalyzed α-hydrazination of a sterically congested aldehyde with excellent enantioselectivity. 2-Bromo-N-ethylpyridinium tetrafluoroborate (BEP)-mediated peptide coupling completes the synthesis, being the first approach that does not employ chiral auxiliaries. A novel phenonium-type rearrangement of the indole system occurred when subjecting dihydroxylated 3-tert-prenylindole to Mitsunobu conditions.

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

Novel pyrrolidine heterocycles as CCR1 antagonists

A novel series of pyrrolidine heterocycles was prepared and found to show potent inhibitory activity of CCR1 binding and CCL3 mediated chemotaxis of a CCR1-expressing cell line. A potent, optimized triazole lead from this series was found to have acceptab

Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N-dimethyl-2(R)-aminomethylpyrrolidine)

A series of platinum(II) complexes were synthesised based on the enantiomerically pure amino acid proline. Novel synthetic pathways were developed, adapted from standard peptide chemistry, to produce the 2-aminomethylpyrrolidine (pyrr) ligand and its derivatives with differing arrangements of methyl substituents at the exocyclic amine sites. The crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N,N-dimethyl-2(R)-aminomethylpyrrolidine) is reported and the five-membered ligand ring has been shown to be in an envelope conformation. Cytotoxicity studies were carried out on the ovarian cancer A2780 tumour cell line and its cisplatin-resistant variant, A2780cisR. Remarkably good activity was seen for several of the drugs when compared to cisplatin despite the addition of substantial steric bulk to the amine groups, and there was a lack of cross-resistance with cisplatin seen for some compounds.

ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES and INFLAMMATION

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.